Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07)
Ciruelos, Eva M., Montaño, Alvaro, Rodríguez, César A., González‐Flores, Encarnación, Lluch, Ana, Garrigós, Laia, Quiroga, Vanesa, Antón, Antonio, Malón, Diego, Chacón, Jose I., Velasco, Montserrat, Gonzalez‐Cortijo, Lucía, Jolis, Laura, Echarri, María J., Muñoz, Montse, Pascual, Tomás, Amigo, Yolanda, Casas, Maribel, Carrasco, Eva, Casas, Ana
Published in European journal of cancer care (01.07.2020)
Published in European journal of cancer care (01.07.2020)
Get full text
Journal Article